BIOVAXYS ANNOUNCES complete inhibition of ACE-2 binding activity of hapten-modified SARS-CoV-2 protein

SUGGESTS superior cardiAC safety compared to mRNA AND ADENOVIRUS VECTOR vaccines VANCOUVER, BC, Feb. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAX) ("BioVaxys" or "Company") announced today that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protei...